Ultomiris for Paroxysmal Nocturnal Hemoglobinuria

News
Article

Ultomiris

ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)

Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria

Dosage: intravenous infusion only

  • 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance

  • 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance

  • 100kg ≤  X – 3,000mg leading, 3,600 maintenance

Contraindications: patients with unresolved Neisseria Meningitidis infection.

 

​Click here for more prescribing information

Recent Videos
Related Content
FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

Ashley Gallagher
June 2nd 2025
Article

The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Hydrocortisone Oral Solution for Adrenocortical Insufficiency

FDA Approves Hydrocortisone Oral Solution for Adrenocortical Insufficiency

Ashley Gallagher
May 29th 2025
Article

The replacement therapy is indicated for patients 5 years and older, marking the first approval for an oral solution form of hydrocortisone.

FDA Grants Interchangeability Designation to Adalimumab-Bwwd for Humira

FDA Grants Interchangeability Designation to Adalimumab-Bwwd for Humira

Ashley Gallagher
May 28th 2025
Article

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.

FDA Approves Ustekinumab-Hmny as Biosimilar to Stelara

FDA Approves Ustekinumab-Hmny as Biosimilar to Stelara

Ashley Gallagher
May 27th 2025
Article

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.

FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body

FDA Approves Roflumilast Foam For Plaque Psoriasis of Scalp, Body

Ashley Gallagher
May 22nd 2025
Article

The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

© 2025 MJH Life Sciences

All rights reserved.